Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients.

ABSTRACT: Treatment with small-molecule inhibitors, guided by precision medicine has improved patient outcomes in multiple cancer types. However, these compounds are often not effective against central nervous system (CNS) tumors. The failure of precision medicine approaches for CNS tumors is frequently attributed to the inability of these compounds to cross the blood-brain barrier (BBB), which impedes intratumoral target engagement. This is complicated by the fact that information on CNS penetration in CNS-tumor patients is still very limited. Herein, we evaluated cerebrospinal fluid (CSF) drug penetration, a well-established surrogate for CNS-penetration, in pediatric brain tumor patients. We analyzed 7 different oral anti-cancer drugs and their metabolites by high performance liquid chromatograph

SUBMITTER: Guntner AS 

PROVIDER: S-EPMC7268320 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature